The potential role of miR-126, miR-21 and miR-10b as prognostic biomarkers in renal cell carcinoma
The potential role of miR-126, miR-21 and miR-10b as prognostic biomarkers in renal cell carcinoma
复制标题
DOI：
10.3892/ol.2019.10142
复制
发表时间：
2019-05-01
期刊：
影响因子：
2.9
通讯作者：
Sundqvist, Pernilla
中科院分区：
文献类型：
--
作者：
Carlsson, Jessica;Christiansen, Jesper;Sundqvist, Pernilla
肾细胞癌 (RCC) 是最常诊断的肾肿瘤，约占全世界所有恶性肿瘤的 3%。 RCC 的预后差异很大，在疾病早期检测出有复发风险的患者可能会改善患者的预后。目前在临床环境中使用的因素无法可靠地预测疾病的自然史。因此，需要识别可以帮助预测患者结果的新型生物标志物。先前的研究表明，microRNA (miRNA/miR) 是作为 RCC 患者预后生物标志物的潜在候选者。因此，本研究的目的是验证其中 3 种 miRNA 预测 RCC 患者预后的潜力，并研究 RCC 组织中 miRNA 研究的内源控制基因的稳定性。使用逆转录定量聚合酶链反应 (RT-qPCR) 在福尔马林固定石蜡包埋的肿瘤和透明细胞肾细胞癌 (ccRCC) 患者的良性组织中测量 7 种内源对照的表达。分析确定 RNU48 和 U47 是最稳定的内源对照。使用 RT-qPCR 分析 116 名诊断为 ccRCC 患者的肾组织中 miR-126、miR-21 和 miR-10b 的表达。所有三种研究的 miRNA 在恶性和良性组织之间都有差异表达。 miR-126 和 miR-10b 在 ccRCC 的级别和阶段之间也存在差异表达。在单变量模型中，miR-126 的低表达与疾病复发的时间较短相关，但在多变量模型中则不然。本研究的结果表明，在所研究的 3 个 miRNA 中，miR-126 的表达最有可能作为 ccRCC 患者的预后生物标志物。
Renal cell carcinoma (RCC) is the most commonly diagnosed renal tumor, consisting of similar to 3% of all malignancies worldwide. The prognosis of RCC can vary widely, and detecting patients at risk of recurrence at an early stage of disease may improve patient outcome. The factors presently used in a clinical setting cannot reliably predict the natural history of the disease. Therefore, there is a requirement to identify novel biomarkers that can aid in predicting patient outcome. Previous studies have indicated that microRNAs (miRNAs/miRs) are potential candidates as prognostic biomarkers for patients suffering from RCC. Consequently, the aims of the present study were to validate the potential of 3 of these miRNAs to predict the prognosis of patients with RCC, and to investigate the stability of endogenous control genes for miRNA studies in RCC tissues. The expression of 7 endogenous controls was measured using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in formalin-fixed paraffin-embedded tumor and benign tissues from patients suffering from clear cell RCC (ccRCC). The analyses identified RNU48 and U47 as the most stable endogenous controls. The expression of miR-126, miR-21 and miR-10b was analyzed using RT-qPCR in renal tissues from 116 patients diagnosed with ccRCC. All three investigated miRNAs were differentially expressed between malignant and benign tissues. miR-126 and miR-10b were also differentially expressed between grades and stages of ccRCC. In a univariate, but not in a multivariate model, low expression of miR-126 was associated with shorter time to recurrence of the disease. The results of the present study indicate that of the 3 miRNAs investigated, the expression of miR-126 has the strongest potential as a prognostic biomarker for patients suffering from ccRCC.